Xerostomia

 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024

Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
  • “These long-term safety results and metabolic outcomes from the EMERGENT program are extremely encouraging, allowing us to further understand the tolerability profile of KarXT in people living with schizophrenia,” said Roland Chen , MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb.
  • In the pooled analysis, KarXT demonstrated a favorable impact on weight and long-term metabolic profile where most patients experienced stability or improvements on key metabolic parameters over 52 weeks of treatment.
  • In the long-term studies, KarXT was generally well-tolerated across 52 weeks of treatment, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Wednesday, March 20, 2024

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Research case series presents food as medicine as a potential treatment for lupus and other autoimmune diseases

Retrieved on: 
Tuesday, March 19, 2024

ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.

Key Points: 
  • ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.
  • All three women reported that nearly all their symptoms of both diseases resolved after just four weeks of making the dietary changes.
  • "My hope is that these cases generate greater recognition, making patients and clinicians aware of food as medicine as a treatment option for systemic lupus erythematosus and Sjögren's syndrome.
  • This case series also reflects the immediate need for more research into dietary changes as a potential treatment strategy for autoimmune disease."

Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised

Retrieved on: 
Tuesday, March 12, 2024

Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised

Key Points: 


Herbal medicinal product: Silybi mariani fructusArray, F: Assessment finalised

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Retrieved on: 
Wednesday, March 6, 2024

These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ).

Key Points: 
  • These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ).
  • At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA
  • The potent antiviral activities, along with pharmacokinetic profiles of islatravir and lenacapavir, support their development as an investigational once-weekly oral combination regimen.
  • No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

Santé's Expert Commentary on the Danger of Tianeptine or "Gas Station Heroin"

Retrieved on: 
Monday, February 12, 2024

ARGYLE, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- The U.S. Food and Drug Administration (FDA) recently issued a new and urgent warning about using any products, such as Neptune's Fix, that contain tianeptine. They sent a letter on January 11, 2024 to convenience stores, gas stations, vape/smoke shops and other companies advising the retailers to stop selling any tianeptine-containing products. In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.

Key Points: 
  • In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.
  • There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.
  • In fact, tianeptine products are being touted "with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.

  • "There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.

Eating leafy greens could be better for oral health than using mouthwash

Retrieved on: 
Tuesday, January 30, 2024

These treatments have side effects, such as dry mouth, the development of antimicrobial resistance and increased blood pressure.

Key Points: 
  • These treatments have side effects, such as dry mouth, the development of antimicrobial resistance and increased blood pressure.
  • But research has indicated that a molecule called nitrate, which is found in leafy green vegetables, has fewer side effects and offers greater benefits for oral health.
  • Periodontitis is a more advanced form of gum disease, causing damage to the soft tissues and bones supporting the teeth.

Leafy greens may be the secret

  • Leafy greens and root vegetables are bursting with vitamins, minerals, and antioxidants – and it’s no secret that a diet consisting of these vegetables is crucial for maintaining a healthy weight, boosting the immune system, and preventing heart disease, cancer and diabetes.
  • The multiple health benefits of leafy greens are partly because spinach, lettuce and beetroots are brimming with nitrate, which can be reduced to nitric oxide by nitrate-reducing bacteria inside the mouth.
  • However, in the mouth, it helps to prevent the overgrowth of bad bacteria and reduces oral acidity, both of which can cause gum disease and tooth decay.
  • Antimicrobial resistance is a global health concern, predicted to cause 10 million deaths yearly by the year 2050.


In contrast, dietary nitrate is more targeted. Nitrate eliminates disease-associated bacteria, reduces oral acidity and creates a balanced oral microbiome. The oral microbiome refers to all the microorganisms in the mouth. Nitrate offers exciting potential as an oral health prebiotic, which can be used to prevent disease onset or limit disease progression.

How many leafy greens for pearly whites?

  • As a rule of thumb, a generous helping of spinach, kale or beetroot at mealtimes contains about 6-10 mmol of nitrate and offers immediate health benefits.
  • For example, consuming lettuce juice for two weeks reduced gum inflammation and increased healthy bacteria levels in patients with gum disease.


Mia Cousins Burleigh has previously received funding from The Royal Society of Edinburgh. Siobhan Paula Moran does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations

Retrieved on: 
Friday, January 19, 2024

RARITAN, N.J., Jan. 19, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. This FDA action converts the April 2019 accelerated approval of BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study. BALVERSA® is the first oral FGFR kinase inhibitor to be approved, and the first and only targeted treatment for patients with mUC and FGFR alterations.

Key Points: 
  • BALVERSA® is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
  • This FDA action converts the April 2019 accelerated approval of BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study.
  • BALVERSA® is the first oral FGFR kinase inhibitor to be approved, and the first and only targeted treatment for patients with mUC and FGFR alterations.
  • This model is part of the Company's ongoing commitment to provide high-quality products, services, access, and support to healthcare professionals and patients.

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised